文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

健康成人长时间吸入氢气(2.4%)的安全性研究

Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults.
PubMed 文献 · Crit Care Explor · 2021-10-08
一句话结论健康成人经高流量鼻导管吸入2.4%氢气24–72小时未出现临床显著不良事件,但样本仅8例,需更大样本验证安全性。

本研究为前瞻性单臂研究,纳入8名健康成人(18–30岁,50%女性,62%非白种人),经高流量鼻导管(15 L/min)吸入2.4%氢气-医用空气混合气24小时(n=2)、48小时(n=2)或72小时(n=4)。所有受试者均完成研究,无提前终止;由两名外部临床医师及独立数据安全监察委员会核实,未发生临床显著不良事件。与基线相比,生命体征、肺功能、简易精神状态检查、神经查体、心电图及血液学(除血细胞比容和血小板计数有临床无意义升高)、肾、肝、胰、心肌损伤血清学标志物均无临床显著变化。结论认为2.4%氢气吸入在健康成人中似不引起临床显著不良反应,但未来研究需足够把握度进一步评估安全性。

要点

  • 健康成人经高流量鼻导管(15 L/min)吸入2.4%氢气24–72小时,全部8例完成研究,无临床显著不良事件。
  • 由两名外部临床医师和独立数据安全监察委员会核实所有不良事件,未发生临床显著事件。
  • 与基线相比,生命体征、肺功能、简易精神状态检查、神经查体、心电图及多器官血清学标志物均无临床显著变化。
  • 仅血液学出现血细胞比容和血小板计数临床无意义升高,其余血液学、肾、肝、胰、心肌损伤标志物无临床显著变化。
  • 样本仅8例健康成人(18–30岁),作者指出未来研究需足够把握度进一步评估安全性。

适用人群与场景

  • 健康成人8例,年龄18–30岁,50%女性,62%非白种人;研究在三级医院住院条件下进行。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 经高流量鼻导管以15 L/min吸入2.4%氢气-医用空气混合气,暴露时长24小时(n=2)、48小时(n=2)或72小时(n=4)。
  • 暴露前后评估生命体征、患者及护士报告的症状体征(按临床意义分层)、肺功能、12导联心电图、简易精神状态检查、神经查体及血清学检测。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 前瞻性单臂研究,8例健康成人,三级医院单中心;干预为2.4%氢气经高流量鼻导管(15 L/min)吸入24–72小时,无对照组。
  • 全部8例完成研究,无提前终止;无临床显著不良事件,所有不良事件由两名外部临床医师及独立数据安全监察委员会核实。
  • 与基线相比,生命体征、肺功能、简易精神状态检查、神经查体、心电图及血液学(除血细胞比容和血小板计数临床无意义升高)、肾、肝、胰、心肌损伤血清学标志物均无临床显著变化。

证据类型、等级与局限

  • 证据类型:前瞻性单臂研究(非随机、无对照)。
  • 局限:样本仅8例健康成人,作者指出未来研究需足够把握度进一步评估安全性;未在危重病患者中验证。

对床旁实践的改变

  • 本研究仅提示健康成人吸入2.4%氢气24–72小时耐受性良好,不能据此在急诊或ICU常规使用氢气治疗。
  • 适用人群仅为健康成人,不适用于危重病患者;在缺血再灌注损伤、心脏骤停后等场景的有效性与安全性尚未验证。
  • 常见陷阱:将健康成人安全性数据外推至危重病患者,或把研究方案中的2.4%氢气、15 L/min、24–72小时暴露当作临床推荐剂量。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Ischemia-reperfusion injury is common in critically ill patients, and directed therapies are lacking. Inhaled hydrogen gas diminishes ischemia-reperfusion injury in models of shock, stroke, and cardiac arrest. The purpose of this study was to investigate the safety of inhaled hydrogen gas at doses required for a clinical efficacy study.

DESIGN: Prospective, single-arm study.

SETTING: Tertiary care hospital.

PATIENTS/SUBJECTS: Eight healthy adult participants.

INTERVENTIONS: Subjects underwent hospitalized exposure to 2.4% hydrogen gas in medical air via high-flow nasal cannula (15 L/min) for 24 (n = 2), 48 (n = 2), or 72 (n = 4) hours.

MEASUREMENTS AND MAIN RESULTS: Endpoints included vital signs, patient- and nurse-reported signs and symptoms (stratified according to clinical significance), pulmonary function testing, 12-lead electrocardiogram, mini-mental state examinations, neurologic examination, and serologic testing prior to and following exposure. All adverse events were verified by two clinicians external to the study team and an external Data and Safety Monitoring Board. All eight participants (18-30 yr; 50% female; 62% non-Caucasian) completed the study without early termination. No clinically significant adverse events occurred in any patient. Compared with baseline measures, there were no clinically significant changes over time in vital signs, pulmonary function testing results, Mini-Mental State Examination scores, neurologic examination findings, electrocardiogram measurements, or serologic tests for hematologic (except for clinically insignificant increases in hematocrit and platelet counts), renal, hepatic, pancreatic, or cardiac injury associated with hydrogen gas inhalation.

CONCLUSIONS: Inhalation of 2.4% hydrogen gas does not appear to cause clinically significant adverse effects in healthy adults. Although these data suggest that inhaled hydrogen gas may be well tolerated, future studies need to be powered to further evaluate safety. These data will be foundational to future interventional studies of inhaled hydrogen gas in injury states, including following cardiac arrest.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Cole AR, Sperotto F, DiNardo JA, et al. Safety of Prolonged Inhalation of Hydrogen Gas in Air in Healthy Adults. Crit Care Explor. 2021. PMID: 34651133. doi:10.1097/CCE.0000000000000543

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。